Phenylpiracetam Side Effects: What Studies Report
The verified literature summarised here contains no controlled human adverse-event trial of phenylpiracetam. What exists is animal pharmacology on the S-enantiomer, a class-level review of piracetam-like drugs, and two analytical and market-surveillance papers documenting unauthorized nootropic ingredients in supplements sold in Europe and Australia. That means published safety questions about phenylpiracetam are answered mainly by mechanism and product-quality data, not by measured side-effect rates in people. This page reports what researchers stated and marks the gaps plainly.
Questions about phenylpiracetam tolerability are usually answered online with lists of effects that have no peer-reviewed source. This page takes the opposite approach: it reports only what the verified papers state, and it names the places where human safety evidence is absent rather than filling them in. This page is for educational purposes only and is not medical advice; consult a licensed physician about any question involving a substance, symptom or medication.
What phenylpiracetam is in the published record
Phenylpiracetam is a phenyl-substituted analogue within the racetam family. A 2010 review in Drugs surveyed piracetam and piracetam-like drugs and traced the class from basic science through to novel clinical applications in central nervous system disorders (https://pubmed.ncbi.nlm.nih.gov/20166767/). That review is the main class-level reference point in the verified set, and its stated scope was pharmacology and clinical application in CNS disorders rather than a quantified adverse-event catalogue for individual analogues such as phenylpiracetam (https://pubmed.ncbi.nlm.nih.gov/20166767/).
A separate strand of the literature treats phenylpiracetam not as a therapeutic agent but as an ingredient turning up in consumer products. A 2023 review in Drug Testing and Analysis examined unauthorized ingredients in "nootropic" dietary supplements, covering their history, pharmacology, prevalence, international regulations and potential as doping agents (https://pubmed.ncbi.nlm.nih.gov/37357012/). That framing matters for safety interpretation: the review's subject was substances appearing in supplements without authorisation as ingredients, which is a different evidentiary situation from a medicine with a regulator-reviewed safety label (https://pubmed.ncbi.nlm.nih.gov/37357012/).
No dose figures appear anywhere on this page, because the verified papers cited here do not supply human dosing schedules for phenylpiracetam. Where a number cannot be supported by a cited source, it is omitted rather than paraphrased from secondary commentary.
Phenylpiracetam Adverse Effects: What Studies Report
Animal pharmacology: the S-enantiomer
The most specific phenylpiracetam finding in the verified set comes from a 2017 paper in Pharmacology, Biochemistry, and Behavior. Researchers characterised S-phenylpiracetam as a selective dopamine transporter (DAT) inhibitor and reported that it reduced body weight gain without influencing locomotor activity (https://pubmed.ncbi.nlm.nih.gov/28743458/). Two details of that report are easy to lose in summary. First, the compound tested was the S-enantiomer, not the racemic mixture that appears in consumer products, so the study's conclusions apply to the isolated enantiomer the researchers administered (https://pubmed.ncbi.nlm.nih.gov/28743458/). Second, the absence of an effect on locomotor activity was itself a reported finding, distinguishing the profile the study described from classical psychostimulants (https://pubmed.ncbi.nlm.nih.gov/28743458/).
A reduction in body weight gain is a physiological outcome, not automatically an "adverse event", and the study reported it as a measured endpoint in an animal model rather than as a tolerability signal in people (https://pubmed.ncbi.nlm.nih.gov/28743458/). Mechanistically, DAT inhibition is the property most often invoked in discussions of stimulant-like concerns, and that mechanism is what the study identified (https://pubmed.ncbi.nlm.nih.gov/28743458/). Mechanism, however, predicts hypotheses rather than event rates; it does not establish how often any effect occurred in humans.
Class-level literature on piracetam-like drugs
The 2010 Drugs review grouped piracetam with structurally related agents and discussed their basic science alongside clinical applications in CNS disorders (https://pubmed.ncbi.nlm.nih.gov/20166767/). Class reviews of this kind are frequently cited as if they validated the safety of every analogue in the family. That inference does not follow from what the review set out to do: its stated remit was the pharmacology and emerging clinical uses of the class in CNS disorders (https://pubmed.ncbi.nlm.nih.gov/20166767/). Structural analogues within a family can differ in transporter affinity, and the 2017 animal work reported a selective DAT-inhibiting profile for S-phenylpiracetam specifically (https://pubmed.ncbi.nlm.nih.gov/28743458/).
Where human adverse-event data is absent
This is the central point of the page, stated plainly: the verified literature summarised here does not include a controlled human trial reporting phenylpiracetam side-effect frequencies, severity gradings, withdrawal rates, laboratory abnormalities, drug-interaction outcomes or long-term follow-up. The 2017 study was animal pharmacology on the S-enantiomer (https://pubmed.ncbi.nlm.nih.gov/28743458/); the 2010 paper was a class review focused on pharmacology and CNS applications (https://pubmed.ncbi.nlm.nih.gov/20166767/); and the two remaining papers examined products and markets rather than measured clinical endpoints in participants (https://pubmed.ncbi.nlm.nih.gov/37357012/).
Absence of published adverse-event data is not the same as evidence of safety. It means the question "how often does effect X occur, and in whom?" has no answer in this evidence set, and that any confident percentage circulating elsewhere is not traceable to these papers.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeProduct-Level Risks in Nootropic Supplements: What Studies Report
Unauthorized ingredients in products marketed as nootropics
The 2023 Drug Testing and Analysis review addressed unauthorized ingredients in "nootropic" dietary supplements and assessed their prevalence as well as the international regulatory frameworks applying to them (https://pubmed.ncbi.nlm.nih.gov/37357012/). In practical terms, the review's premise was that substances not authorised as dietary-supplement ingredients have been found in products sold as cognitive enhancers, and it also considered their potential as doping agents (https://pubmed.ncbi.nlm.nih.gov/37357012/). For anyone reading about tolerability, this creates a second layer of uncertainty on top of the missing clinical data: when the contents of a product are not reliably known, effects experienced cannot be attributed to a single named ingredient.
Market surveillance across Europe and Australia
A 2025 paper in the Journal of Xenobiotics reported a market-surveillance study carried out by 12 official medicines control laboratories, examining the occurrence of illicit smart drugs or nootropics in Europe and Australia and their associated dangers (https://pubmed.ncbi.nlm.nih.gov/40558871/). The study's design is worth noting for what it can and cannot show: laboratory analysis of marketed products documents what was present in samples and the hazards the authors associated with that market, and it was not structured as a clinical safety trial in volunteers (https://pubmed.ncbi.nlm.nih.gov/40558871/). The two market-facing papers therefore converge on product identity and regulatory status as documented risk domains, while neither reported measured human side-effect rates for phenylpiracetam (https://pubmed.ncbi.nlm.nih.gov/40558871/).
Regulatory and doping context
Regulatory status is a factual matter and sits alongside pharmacology in the safety picture. The 2023 review discussed international regulations covering nootropic supplement ingredients and considered the potential of such substances as doping agents (https://pubmed.ncbi.nlm.nih.gov/37357012/). The 2025 surveillance paper framed its subject as illicit smart drugs or nootropics circulating in Europe and Australia, examined by official medicines control laboratories (https://pubmed.ncbi.nlm.nih.gov/40558871/). Neither paper is a substitute for current national law, and nothing here is legal advice; regulatory classifications differ by country and change over time.
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appFrequently repeated side-effect claims and their evidentiary status
Lists of phenylpiracetam effects — sleep disturbance, irritability, headache, appetite change, diminishing response over time — circulate widely in forums and product copy. None of those frequencies can be sourced to the verified papers cited on this page. The closest mechanistic anchor is the 2017 report that S-phenylpiracetam acted as a selective DAT inhibitor and reduced body weight gain without influencing locomotor activity in the model studied (https://pubmed.ncbi.nlm.nih.gov/28743458/). Translating an animal-model endpoint into an expected human side-effect profile is an inference, not a finding, and the study reported the endpoint it measured rather than a human tolerability outcome (https://pubmed.ncbi.nlm.nih.gov/28743458/).
Evidence summary
| Paper | What it examined | What researchers reported | Bearing on side-effect questions |
|---|---|---|---|
| S-phenylpiracetam, DAT inhibitor (2017) | Animal pharmacology of the S-enantiomer | Selective DAT inhibition; reduced body weight gain without influencing locomotor activity (https://pubmed.ncbi.nlm.nih.gov/28743458/) | Mechanistic and preclinical; no human event rates |
| Piracetam and piracetam-like drugs (2010) | Class review, basic science to CNS applications (https://pubmed.ncbi.nlm.nih.gov/20166767/) | Pharmacology and clinical applications of the class | Class context, not analogue-specific adverse-event data |
| Unauthorized nootropic ingredients (2023) | History, pharmacology, prevalence, regulations, doping potential (https://pubmed.ncbi.nlm.nih.gov/37357012/) | Unauthorized ingredients documented in supplements | Product-identity and regulatory risk |
| OMCL market surveillance (2025) | Illicit smart drugs in Europe and Australia, 12 laboratories (https://pubmed.ncbi.nlm.nih.gov/40558871/) | Occurrence in the market and associated dangers | Market-level hazard, not clinical tolerability |
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeWhat would be needed to close the gap
To answer side-effect questions with numbers rather than mechanism, the literature would need randomised human studies with pre-specified adverse-event collection, defined exposure periods, laboratory monitoring and comparison groups. None of the four verified papers was that kind of study: one was preclinical (https://pubmed.ncbi.nlm.nih.gov/28743458/), one a class review (https://pubmed.ncbi.nlm.nih.gov/20166767/), and two analytical or surveillance work on marketed products (https://pubmed.ncbi.nlm.nih.gov/40558871/). Until such studies exist and are indexed, the honest summary is that the human side-effect profile of phenylpiracetam is uncharacterised in this evidence base.
Related learning
This page covers the safety and adverse-event question only. For the underlying pharmacology, nomenclature, enantiomer distinctions and how the racetam family is studied, the structured lesson sequence at /learn/phenylpiracetam/ teaches that background instead of repeating it here.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeReferences
- S-phenylpiracetam, a selective DAT inhibitor, reduces body weight gain without influencing locomotor activity (Pharmacology, Biochemistry, and Behavior, 2017)
- Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders (Drugs, 2010)
- Unauthorized ingredients in "nootropic" dietary supplements: A review of the history, pharmacology, prevalence, international regulations, and potential as doping agents (Drug Testing and Analysis, 2023)
- The Occurrence of Illicit Smart Drugs or Nootropics in Europe and Australia and Their Associated Dangers: Results from a Market Surveillance Study by 12 Official Medicines Control Laboratories (Journal of Xenobiotics, 2025)
Frequently asked questions
Do published studies list phenylpiracetam side effects in humans?▾
Not in the verified literature summarised here. No controlled human trial in this set reported side-effect frequencies, severity or withdrawal rates for phenylpiracetam. The available papers were animal pharmacology on the S-enantiomer (PMID 28743458), a class review of piracetam-like drugs (PMID 20166767), and analytical work on marketed nootropic products (PMID 37357012). That absence is a gap, not a safety finding.
What did the animal study on S-phenylpiracetam report?▾
Researchers characterised S-phenylpiracetam as a selective dopamine transporter inhibitor and reported that it reduced body weight gain without influencing locomotor activity (PMID 28743458). The compound studied was the isolated S-enantiomer rather than the racemic mixture found in consumer products, so the reported profile applies to what the study administered in an animal model, not to measured human outcomes.
Is phenylpiracetam considered a stimulant in the literature?▾
The 2017 study identified selective dopamine transporter inhibition as the mechanism and reported no influence on locomotor activity, a result that distinguishes the described profile from classical psychostimulant behaviour in that model (PMID 28743458). A 2010 review placed piracetam-like drugs in a class studied for CNS applications rather than as stimulants (PMID 20166767).
Why do reviews mention product-quality problems alongside phenylpiracetam?▾
A 2023 review examined unauthorized ingredients in "nootropic" dietary supplements, including their prevalence, international regulations and potential as doping agents (PMID 37357012). A 2025 market-surveillance study by 12 official medicines control laboratories reported the occurrence of illicit smart drugs in Europe and Australia and associated dangers (PMID 40558871). Uncertain product contents complicate attributing any effect to one ingredient.
Does the 2010 racetam review establish that phenylpiracetam is well tolerated?▾
No. The review surveyed piracetam and piracetam-like drugs from basic science to clinical applications in CNS disorders (PMID 20166767); its stated scope was pharmacology and emerging clinical uses rather than a quantified adverse-event catalogue for individual analogues. Analogues can differ pharmacologically, as the selective transporter profile reported for S-phenylpiracetam illustrates (PMID 28743458).
Are there long-term safety or interaction data for phenylpiracetam?▾
None appear in the verified papers cited here. The preclinical study reported a body-weight-gain endpoint in an animal model (PMID 28743458), and the surveillance and review papers addressed products, prevalence and regulation rather than long-term clinical follow-up or drug interactions (PMID 40558871, PMID 37357012). Long-term human safety remains uncharacterised in this evidence base.
What kind of research would answer side-effect questions more directly?▾
Randomised human studies with pre-specified adverse-event collection, defined exposure windows, laboratory monitoring and comparison groups. None of the verified papers used that design: one was preclinical (PMID 28743458), one a class review (PMID 20166767), and two examined marketed products and regulation (PMID 40558871, PMID 37357012). This page is educational only and is not medical advice.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.